NCT05287308

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	doxorubicin	doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
DRUG	epirubicin	epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
DRUG	pirarubicin	pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
DRUG	cyclophosphamide	cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
DRUG	albumin-bound paclitaxel	albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
DRUG	paclitaxel	paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
DRUG	docetaxel	docetaxel 80\~100mg/m2, i.v., d1, q3w.

Timeline

• Start date: 2022-03-01
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2022-03-18
• Last updated: 2022-03-31

Locations

1 site across 1 country: China